Merus NV - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Merus NV Company

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Merus NV Info



Ticker SymbolMRUS

Company nameMerus NV

IPO dateMay 19, 2016

CEODr. Sven Ante (Bill) Lundberg, M.D.

Number of employees260

Security typeOrdinary Share

Fiscal year-endMay 19

AddressYalelaan 62

CityUTRECHT

Stock exchangeNASDAQ Global Market Consolidated

CountryNetherlands

Postal code3584 CM

Phone310302538800

Websitehttps://merus.nl/

Ticker SymbolMRUS

IPO dateMay 19, 2016

CEODr. Sven Ante (Bill) Lundberg, M.D.

Company Executives of Merus NV



Name

Name/Position

Position

Shareholding

Change

Dr. Sven Ante (Bill) Lundberg, M.D.

President, Chief Executive Officer, Executive Director

198.74K

+55.46%

Dr. Anand Mehra, M.D.

Non-Executive Independent Chairman of the Board

--

Mr. Peter B. Silverman, J.D.

Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal

--

Ms. Sherri Spear

Investor Relations and Corporate Communications

--

Mr. Jason Haddock

Director

--

Dr. Fabian Zohren, M.D., Ph.D

Chief Medical Officer

--

Dr. Maxine Gowen, Ph.D.

Non-Executive Independent Director

--

Mr. Leonard (Len) Kanavy

Non-Executive Independent Director

--

Dr. Victor Sandor, M.D.

Non-Executive Independent Director

--

Mr. Gregory D. (Greg) Perry

Chief Financial Officer

--

Name

Name/Position

Position

Shareholding

Change

Dr. Sven Ante (Bill) Lundberg, M.D.

President, Chief Executive Officer, Executive Director

198.74K

+55.46%

Dr. Anand Mehra, M.D.

Non-Executive Independent Chairman of the Board

--

Mr. Peter B. Silverman, J.D.

Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal

--

Ms. Sherri Spear

Investor Relations and Corporate Communications

--

Mr. Jason Haddock

Director

--

Dr. Fabian Zohren, M.D., Ph.D

Chief Medical Officer

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Fri, Aug 15

Shareholders

Shareholder Types

Shareholders

Proportion

Fidelity Management & Research Company LLC

8.20%

Paradigm BioCapital Advisors LP

5.65%

RTW Investments L.P.

5.27%

Wellington Management Company, LLP

4.91%

Commodore Capital LP

4.65%

Other

71.32%

Shareholders

Proportion

Fidelity Management & Research Company LLC

8.20%

Paradigm BioCapital Advisors LP

5.65%

RTW Investments L.P.

5.27%

Wellington Management Company, LLP

4.91%

Commodore Capital LP

4.65%

Other

71.32%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

36.78%

Hedge Fund

34.50%

Investment Advisor

25.54%

Corporation

1.93%

Venture Capital

1.77%

Research Firm

1.13%

Private Equity

0.93%

Individual Investor

0.37%

Pension Fund

0.36%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

431

77.28M

101.92%

-5.29M

2025Q2

411

75.46M

99.77%

-10.50M

2025Q1

420

74.82M

101.12%

-10.15M

2024Q4

398

74.69M

108.18%

-7.45M

2024Q3

373

72.99M

107.03%

-6.71M

2024Q2

355

69.91M

103.77%

+7.77M

2024Q1

315

57.35M

97.63%

-5.32M

2023Q4

282

57.36M

99.41%

-5.55M

2023Q3

268

57.60M

100.50%

+2.76M

2023Q2

260

49.90M

100.83%

+114.35K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Fidelity Management & Research Company LLC

6.22M

8.2%

+593.98K

+10.56%

Jun 30, 2025

Paradigm BioCapital Advisors LP

4.28M

5.65%

+727.89K

+20.48%

Jun 30, 2025

RTW Investments L.P.

4.00M

5.28%

-168.84K

-4.05%

Jun 30, 2025

Wellington Management Company, LLP

3.73M

4.92%

-991.45K

-21.01%

Jun 30, 2025

Commodore Capital LP

3.52M

4.65%

-947.84K

-21.19%

Jun 30, 2025

Deerfield Management Company, L.P.

3.38M

4.47%

+210.70K

+6.64%

Jun 30, 2025

Avoro Capital Advisors LLC

3.16M

4.16%

+155.56K

+5.19%

Jun 30, 2025

T. Rowe Price Associates, Inc.

2.26M

2.98%

+1.17M

+106.44%

Jun 30, 2025

Holocene Advisors, LP

2.23M

2.94%

+351.62K

+18.77%

Jun 30, 2025

Westfield Capital Management Company, L.P.

2.04M

2.69%

+541.17K

+36.05%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

Harbor Health Care ETF

4.61%

ALPS Medical Breakthroughs ETF

4.1%

Tema Oncology ETF

3.91%

AltShares Merger Arbitrage ETF

3.3%

NYLI Merger Arbitrage ETF

3.1%

Goldman Sachs Hedge Industry VIP ETF

2.89%

First Trust IPOX Europe Equity Opportunities ETF

2.59%

Simplify Health Care ETF

2.48%

Invesco Dorsey Wright Healthcare Momentum ETF

1.5%

AltShares Event-Driven ETF

1.39%

Harbor Health Care ETF

Proportion4.61%

ALPS Medical Breakthroughs ETF

Proportion4.1%

Tema Oncology ETF

Proportion3.91%

AltShares Merger Arbitrage ETF

Proportion3.3%

NYLI Merger Arbitrage ETF

Proportion3.1%

Goldman Sachs Hedge Industry VIP ETF

Proportion2.89%

First Trust IPOX Europe Equity Opportunities ETF

Proportion2.59%

Simplify Health Care ETF

Proportion2.48%

Invesco Dorsey Wright Healthcare Momentum ETF

Proportion1.5%

AltShares Event-Driven ETF

Proportion1.39%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data